0001209191-19-014993.txt : 20190301 0001209191-19-014993.hdr.sgml : 20190301 20190301163112 ACCESSION NUMBER: 0001209191-19-014993 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190227 FILED AS OF DATE: 20190301 DATE AS OF CHANGE: 20190301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Danziger Asaf CENTRAL INDEX KEY: 0001654435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 19649872 MAIL ADDRESS: STREET 1: 5 NACHUM CHAT ST. CITY: TIRAT HACARMEL STATE: L3 ZIP: 5112302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-27 0 0001645113 NovoCure Ltd NVCR 0001654435 Danziger Asaf C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 1 1 0 0 Chief Executive Officer Ordinary Shares 2019-02-27 4 M 0 9260 52.90 A 233757 D Ordinary Shares 2019-02-28 4 M 0 903 14.37 A 234660 D Ordinary Shares 2019-02-28 4 S 0 903 54.395 D 233757 D Restricted Stock Units 0.00 2019-02-27 4 M 0 9260 0.00 D 2019-02-27 Ordinary Shares 9260 18518 D Options to Buy Ordinary Shares 14.37 2019-02-28 4 M 0 903 0.00 D 2025-02-23 Ordinary Shares 903 353887 D These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. On February 28, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 903 shares in multiple trades at prices ranging from $54.37 to $54.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Fully vested as of the date hereof. Fully vested and currently exercisable as of the date hereof. By: /s/ Kimberly Burke, Attorney in fact for Asaf Danziger 2019-03-01